Incidence, Clinical Profiles, and Management Patterns of Post-COVID-19 Cardiomyopathy: A Multi-Center Study from Tripoli, Libya
Keywords:
Cardiomyopathy; COVID-19; Dilated Cardiomyopathy; Heart Failure; Post-COVID SyndromeAbstract
Post-COVID-19 cardiomyopathy has emerged as a significant sequela among recovered patients, but data from North Africa
remain limited.
The goal of the study is to assess the incidence, clinical characteristics, diagnostic methods, and therapeutic management of post
COVID-19 cardiomyopathy in Libyan hospitals at the capital Tripoli. A retrospective observational study was conducted in three
tertiary hospitals in Tripoli, Libya, including patients diagnosed with cardiomyopathy post-COVID-19 infection during 2022.
Among 134 patients (mean age 58.4 ± 11.7 years), dilated cardiomyopathy (67%) was the predominant subtype. Echocardiography
was the primary diagnostic modality (98%). Standard medical therapy was employed in 58% of cases, and 12-month mortality
was 19.4%.
Post-COVID-19 cardiomyopathy in Tripoli presents a major healthcare burden, with delayed diagnosis, limited access to
advanced diagnostics, and inconsistent adherence to evidence-based treatments. Findings highlight the need for local guidelines
to standardize care and improve patient outcomes in this high-risk population.
